A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

July 31, 2014

Conditions
Chronic Hepatitis C
Interventions
DRUG

PEG-IFN-SA /RBV low dose

24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3

DRUG

PEG-IFN-SA /RBV middle dose

24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3

DRUG

PEG-IFN-SA /RBV high dose

24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3

DRUG

Pegasys /RBV

24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3

Trial Locations (52)

Unknown

The First Affiliated Hospital of Fujian Medical University, Fuzhou

First Affiliated Hospital of Lanzhou University, Lanzhou

Guangdong General Hospital, Guangzhou

Guangzhou Eighth People's Hospital, Guangzhou

Nanfang Hospital Southern Medical Unbiversity, Guangzhou

The third people's hospital of Shenzhen, Shenzhen

The First Affiliated Hospital of Guangxi Medical University, Nanning

Third Affiliated Hospital, Hebei Medical University, Shijiazhuang

The First Affiliated Hospital of Harbin Medical University, Harbin

The Second Affiliated Hospital of Harbin Medical University, Harbin

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

First Affiliated Hospital of Zhengzhou University, Zhengzhou

Henan Provincial People's Hospital, Zhengzhou

Tongji Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan

Union hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

The Second Xiangya Hospital of Central South University, Changsha

Xiangya Hospital Central-South University, Changsha

Jiangsu province hospital, Nanjing

The Second Hospital of Nanjing, Nanjing

The first affiliated hospital of suzhou university, Suzhou

First Affiliated Hospital of Nanchang University, Nanchang

The First Affiliated Hospital of Jilin University, Changchun

Yanbian University Hospital (Yanbian Hospital), Yanji

The Sixth People's Hospital of Shenyang, Shenyang

First Affiliated Hospital Of Medical College of Xian Jiaotong University, Xi'an

Second Affiliated Hospital Of Medical College of Xian Jiaotong University, Xi'an

Tangdu Hospital , , Fourth Military Medical University, Xi'an

Jinan Infectious Disease Hospital, Jinan

Qilu Hospital of Shandong university, Jinan

Shandong Provincial Hospital, Jinan

Qingdao Municipal Hospital, Qingdao

The First Hospital of Shanxi Medical University, Taiyuan

Sichuan Academy of Medical Science &Sichuan Provincial People's Hospital, Chengdu

West China Hospital, Sichuan University, Chengdu

The First Teaching Hospital of Xinjiang Medical University, Ürümqi

Xixi Hospital of Hangzhou, Hangzhou

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

302 Military Hospital of China, Beijing

Beijing Ditan Hospital, Capital Medical University, Beijing

Beijing Youan Hospital, Capital Medical University, Beijing

Beijing Youyi Hospital, capital Medical University, Beijing

General Hospital of Beijing Military Region, Beijing

Peking Union Medical College Hospital, Beijing

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

Chongqing Southwest Hospital, Chongqing

Daping Hospital, Research Institute of Surgery Third Military Medical University, Chongqing

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Ruijing Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai Public Health Clinical Center, Shanghai

Tianjin Infectious Disease Hospital, Tianjin

All Listed Sponsors
lead

Beijing Kawin Technology Share-Holding Co., Ltd.

INDUSTRY

NCT01908335 - A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter